My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Moexipril HCl (RS-10085)
    Moexipril HCl (RS-10085)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1795
    CAS #: 82586-52-5Purity ≥98%

    Description: Moexipril HCl (RS-10085) is a potent and orally bioactive nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure. As a potent ACE inhibitor, Moexipril hydrochloride blocks the conversion of angiotensin I to angiotensin II. Moexipril in addition, has cardioprotective effects mediated through a combination of angiotensin II inhibition and bradykinin proliferation. The proliferation of bradykinin stimulates the production of prostaglandin E2 and nitric oxide.

    References: Eur J Pharmacol. 1999 May 28;373(1):21-33; J Endocrinol. 1997 Sep;154(3):467-74.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)535.03
    FormulaC₂₇H₃₅ClN₂O₇
    CAS No.82586-52-5
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: ≥ 100 mg/mL (186.91 mM)
    Water: <1 mg/mL
    Ethanol: N/A
    Other info

    Synonyms: SPM-925; SPM 925; SPM925; CI-925; CI 925; CI925; RS 10085; RS-10085; RS10085; Moexipril. trade name Univasc.

    Chemical Name: 2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride

    InChi Key: JXRAXHBVZQZSIC-QGCARJLFSA-N

    InChi Code: InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22?;/m0./s1

    SMILES Code: O=C(C1N(C([[email protected]@H](N[[email protected]](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.[H]Cl           

    SMILESO=C([[email protected]]1N(C([[email protected]@H](N[[email protected]](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.Cl


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Moexipril dose-dependently reduces the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+. Moexipril and enalapril attenuates staurosporine-induced neuronal apoptosis as determined by nuclear staining with Hoechst 33258.

    In VivoMoexipril (0.3 mg/kg) significantly reduces brain damage after focal ischemia as compared to control mice. Moexipril (0.01 mg/kg) is able to reduce the infarct volume in the rat model after focal cerebral ischemia.  Moexipril reduces blood pressure after the first week of treatment but it has no apparent effect on either the proximal tibial metaphysis or the tibial shaft in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Moexipril combined with hydrochlorothiazide (HCTZ) exhibits a much more potent hypotensive effect and has the same effect on bone mass and dynamic end-points as HCTZ alone. Moexiprilat exhibits a higher inhibitory potency than enalaprilat against both plasma ACE and purified ACE from rabbit lung. Moexipril (0.1-30 mg/kg/day) lowers blood pressure and differentially inhibits ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. Moexipril (10 mg/kg/day) leads to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. 
    Animal modelRats
    Formulation & Dosage0.3 mg/kg
    References

    Eur J Pharmacol. 1999 May 28;373(1):21-33; J Endocrinol. 1997 Sep;154(3):467-74. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?